ClinicalTrials.gov
public full text
Public Domain
The Role of Orexin in Human Panic Disorder
The purpose of this study is to provide some information (pilot data) about whether the study drug, suvorexant, (1) affects levels of orexin in people with panic disorder, and (2) is associated with decreased panic symptoms in response to a carbon dioxide (CO2) challenge.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use#867187
- Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder#908683
- Genetic Causes of Panic Disorder#992909
- The orexin system as a pharmacological target in inflammation: peripheral mechanisms and safety implications.#465221
- Increased prevalence of white matter hyperintensities in patients with panic disorder#326593
Record · ID 834148
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive